These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33013255)

  • 41. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
    Pokhrel R; Chapagain P; Siltberg-Liberles J
    J Med Microbiol; 2020 Jun; 69(6):864-873. PubMed ID: 32469301
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
    Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
    Bharadwaj S; Dubey A; Yadava U; Mishra SK; Kang SG; Dwivedi VD
    Brief Bioinform; 2021 Mar; 22(2):1361-1377. PubMed ID: 33406222
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
    Fischer A; Sellner M; Neranjan S; Smieško M; Lill MA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment.
    Boopathi S; Poma AB; Kolandaivel P
    J Biomol Struct Dyn; 2021 Jun; 39(9):3409-3418. PubMed ID: 32306836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
    de Oliveira OV; Rocha GB; Paluch AS; Costa LT
    J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.
    Kumar A; Loharch S; Kumar S; Ringe RP; Parkesh R
    Comput Struct Biotechnol J; 2021; 19():424-438. PubMed ID: 33391634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.
    Pulakuntla S; Lokhande KB; Padmavathi P; Pal M; Swamy KV; Sadasivam J; Singh SA; Aramgam SL; Reddy VD
    Virusdisease; 2021 Dec; 32(4):690-702. PubMed ID: 34307771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors.
    Hamed M; El-Hasab M; Mansour FR
    Virusdisease; 2021 Jun; 32(2):279-285. PubMed ID: 33948452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study.
    Srivastava V; Naik B; Godara P; Das D; Mattaparthi VSK; Prusty D
    Mol Divers; 2024 Jun; 28(3):1093-1107. PubMed ID: 37079243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modern drug discovery applications for the identification of novel candidates for COVID-19 infections.
    Rani I; Kalsi A; Kaur G; Sharma P; Gupta S; Gautam RK; Chopra H; Bibi S; Ahmad SU; Singh I; Dhawan M; Emran TB
    Ann Med Surg (Lond); 2022 Aug; 80():104125. PubMed ID: 35845863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA Warns Coronavirus Outbreak May Disrupt Supply of Critical Medical Products.
    Stephenson J
    JAMA Health Forum; 2020 Feb; 1(2):e200222. PubMed ID: 36218644
    [No Abstract]   [Full Text] [Related]  

  • 59. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
    Brown AS; Ackerley DF; Calcott MJ
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus.
    Jiang Y; Liu L; Manning M; Bonahoom M; Lotvola A; Yang Z; Yang ZQ
    J Biomol Struct Dyn; 2022 Feb; 40(3):1331-1346. PubMed ID: 33016237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.